GLEN ALLEN, Va. , May 7, 2024 /CNW/ — Remidio Inc., a health technology innovator developing cutting-edge technologies to combat global blindness from diabetic retinopathy, glaucoma, AMD and cataracts. is poised to achieve important goals. milestone.
Remidio Inc. is excited to put its 1,000th FOP-NM handheld fundus camera into the hands of U.S. healthcare providers this quarter. Since 2019, these devices have supported the diabetic retinopathy screening efforts of more than 3,500 high-volume healthcare providers in the United States.
Remidio's FOP NM enables retinal screening anytime, anywhere. (PRNewsfoto/Remidio Innovative Solutions)
Remidio's FOP-NM is the world's first smartphone-based, non-mydriatic fundus camera that eliminates the need for patient dilation and is rapidly revolutionizing retinal examinations in the United States. It has an equal impact within the clinic and outside of it.
The FOP-NM is an easy-to-use, easy-to-train retinal camera that provides excellent image quality and can be used by medical professionals and non-professionals (nurses, other health care workers) in the clinic, at home, in the emergency room, etc. Enables retinal examinations to be performed anywhere. or a remote rural medical center.
The device's portability has also been widely accepted by academic health systems such as the University of Virginia and other universities.
Added Dr. Arjun Dilgangi, assistant professor of ophthalmology at the University of Virginia: My goal at the end of the day is to improve access to screening, and this is certainly one of the more powerful tools to do that. ”
Many handheld fundus cameras tout “superior image quality,” but Remidio's FOP-NM stands out. In a comparative clinical validation study published in Nature Eye, Remidio's FOP-NM provided image quality comparable to the “imaging gold standard.”
FOP-NM's clinically validated technology, along with its ease of use, results in a workflow for screening retinal conditions that makes image acquisition easy, even for beginners.
Erik Hafkey, Remidio's chief commercial officer, added: “Our goal is to impact the lives of the approximately 30 million people in the United States who are at risk for diabetic retinopathy. To do so, Remidio needs new partnerships with proven technology and AI SaMD hardware and telemedicine platform for collaboration between companies and healthcare providers to bring care closer to patients. The vision of using retinal imaging to display a “window into the body” extends beyond eye diseases. The Remidio device's portability, affordability, and ease of use make it a natural fit into existing clinical workflows, allowing us to quickly scale up the effectiveness of this technology. ”
As Remidio continues to break new ground with technology and collaboration, Remidio's team of more than 170 people is committed to delivering healthier vision in a world where advanced technologies and their users come together to ensure eye health for all. We remain dedicated to one vision: Building tomorrow. One vision at a time makes a difference in the lives of millions of people.
Remidio is an innovative ISO 13485 certified medical device company that aims to impact preventable blindness by developing smart, easy-to-use and accessible technology. Remidio's CE marked and FDA 510k registered medical devices have helped him screen and impact over 15 million patients in over 40 countries around the world.
Media Contact: Eric Hufkey
chief commercial officer
[email protected]
+1 – 888-627-1416
Photo: https://mma.prnewswire.com/media/2405447/Remidio_s_FOP_NM.jpg
Logo: https://mma.prnewswire.com/media/2405840/Remidio_Innovative_Solutions_Logo.jpg
SOURCE Remidio's innovative solution
